Kerr Douglas 4
4 · Dyne Therapeutics, Inc. · Filed May 14, 2026
Research Summary
AI-generated summary of this filing
Dyne Therapeutics CMO Kerr Douglas Sells 1,564 Shares
What Happened
- Kerr Douglas, Chief Medical Officer of Dyne Therapeutics (DYN), had 1,564 shares sold on May 13, 2026 for a total of $28,715. The reported weighted-average price was $18.36 per share (sales executed between $18.20 and $18.41).
Key Details
- Transaction date: 2026-05-13; Form filed: 2026-05-14.
- Transaction type: Sale (disposition) of 1,564 shares; total proceeds reported $28,715 (weighted avg $18.36).
- Price range: $18.20 to $18.41 (multiple transactions; issuer/staff may request breakdown).
- Reason: Automatic sale to satisfy tax withholding on RSUs that vested on Feb 12, 2026 (per footnote). The sale was pursuant to a binding RSU agreement and was not a discretionary trade by the insider.
- Holdings after transaction: Filing notes reported holdings include 148,313 unvested RSUs (as disclosed in the filing).
Context
- This was a routine, non-discretionary sale to cover tax withholding on vested restricted stock units, not an opportunistic open-market sell signal. The filing indicates the sale is consistent with a binding contract and the affirmative defense under Rule 10b5-1.
Insider Transaction Report
Form 4
Kerr Douglas
Chief Medical Officer
Transactions
- Sale
Common Stock
[F1][F2][F3]2026-05-13$18.36/sh−1,564$28,715→ 170,042 total
Footnotes (3)
- [F1]Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.20 to $18.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
- [F3]Includes 148,313 unvested RSUs.
Signature
/s/ Ron Caponigro, Attorney-in-Fact|2026-05-14